FIELD: biotechnology.
SUBSTANCE: there are presented: a polypeptide composition specifically interacting with human mesothelin, an immunoreactive cell for enhancing the immune response to cancer and a method for preparing the same, a pharmaceutical composition for enhancing the immune response to cancer, a nucleic acid composition for producing an immunoreactive cell and an expression vector. Also disclosed is a kit for enhancing the immune response to cancer, a method of treating neoplasia in a subject and treating a subject having a recurrent neoplasia, method of increasing or prolonging the survival rate of a subject having neoplasia, a method of reducing a tumour load in a subject, a method of increasing production of an immunoactivating cytokine in response to a cancer cell or a pathogen in a subject, a method of treating an inflammatory disease in a subject and a method for preventing transplant rejection in a subject.
EFFECT: invention is used to enhance the immune response to cancer, as well as to increase the production of an immunoactivating cytokine in response to a cancer cell or pathogen in a subject.
90 cl, 13 tbl, 94 dwg, 6 ex
Title | Year | Author | Number |
---|---|---|---|
TYPES OF COMBINATION THERAPY USING CHIMERIC ANTIGEN RECEPTORS AND PD-1 INHIBITORS | 2017 |
|
RU2809160C2 |
CHIMERIC ANTIGENE RECEPTORS TARGETTING FLT3 | 2018 |
|
RU2820859C2 |
MUC16-SPECIFIC CHIMERIC ANTIGEN RECEPTORS AND THEIR USE | 2019 |
|
RU2795198C2 |
CHIMERIC ANTIGEN RECEPTORS AND BINDING AGENTS TARGETING DLL3 | 2020 |
|
RU2822366C2 |
CHIMERIC ANTIGENIC (CAR) RECEPTOR AGAINST CD123 FOR USE IN TREATING MALIGNANT TUMORS | 2015 |
|
RU2724999C2 |
CHIMERIC ANTIGEN RECEPTORS TARGETING CD70 | 2019 |
|
RU2801824C2 |
TREATMENT OF MALIGNANT NEOPLASM USING HUMANIZED CHIMERIC ANTIGEN RECEPTOR AGAINST BCMA | 2015 |
|
RU2751660C2 |
COMPOSITIONS AND METHODS OF SELECTIVE PROTEIN DEGRADATION | 2018 |
|
RU2811700C2 |
CHIMERIC ANTIGEN RECEPTOR | 2018 |
|
RU2770002C2 |
CHIMERIC ANTIGEN RECEPTOR | 2016 |
|
RU2752880C2 |
Authors
Dates
2024-07-03—Published
2020-05-18—Filed